DONATE NOW:Urgent Call for Healthy Donors as Blood Supply Drops to Dangerously Low LevelsSchedule Appointment

 

Seasoned executive brings over two decades of business and leadership experience in the pharmaceutical, biotechnology and healthcare fields

Jay Mohr

NEW YORK — New York Blood Center (NYBC) announced today that Joseph S. “Jay” Mohr is joining the organization as Chief Financial and Business Officer. As Chief Financial and Business Officer, Jay will bring years of financial leadership and commercial and business development expertise to the organization and will be responsible for managing the financial, business development, and facilities functions of NYBC.

“Jay’s experience working at the intersection of business and biotechnology makes him an incredible asset to our team, particularly at this important and dynamic time in NYBC’s lifecycle,” said Christopher D. Hillyer, MD, President and CEO, of New York Blood Center. “We are thrilled to welcome Jay to NYBC and look forward to partnering with him as we improve the lives of patients around the world through innovative research and development in the fields of hematology, transfusion medicine and cellular therapies.”

“It is an honor to be joining this prestigious organization that is doing amazing work at a time when pharmaceutical and medical advances are desperately needed,” said Jay Mohr, Chief Financial and Business Officer of New York Blood Center. He commented further “In this role, I am enthusiastic about partnering with the biopharma industry and investor community on the many important assets that are being developed by the NYBC in the fields of hematology, infectious diseases and cell therapies.”

In addition to providing life-saving blood services to hospitals around the country, NYBC has pioneered advancements in transfusion medicine, cellular therapy, hematology and infectious diseases, resulting in new therapies, patents and licenses. NYBC is also playing a critical role in the fight against COVID-19, including collecting and maintaining the nation’s largest supply of COVID-19 convalescent plasma, vaccine and therapeutics research and development and investigation into the body’s immune response to COVID-19.

Having served as CEO or C-level executive of several pharma and life science companies, Jay comes to NYBC with vast leadership experience in general and financial management, as well as  business and corporate development. Before joining NYBC, Jay served as the Chief Operating and Business Officer of AZTherapies, a privately held biopharma company focused on neurodegenerative diseases. In this role, he led or supported fundraising, investor relations, corporate strategy and business development activities. Previously, Jay was co-founder and Managing Director of Locust Walk Partners, a global transaction advisory firm. While there, Jay led or participated in more than 20 transactions valued in aggregate at more than $1 billion.  Prior to Locust Walk, he was co-founder and CEO of Gloucester Pharmaceuticals, which was acquired by Celgene Corporation for over $600 million. Earlier in his career, he led Variagenics, a publicly traded biomarker discovery company, through its merger with Hyseq; prior to that he had P&L responsibility, business unit and commercial leadership roles at EMD Serono and Schering-Plough Corporation.

Jay currently serves on several non-profit boards including the Chairman of the Board of the T1D Exchange, the Maine Technological Institute and the Executive Advisory Board of the Leonard David Institute of Healthcare Economics at the University of Pennsylvania.

Jay graduated from Vanderbilt University with a Bachelor of Arts in Economics and German. He holds his Master of Business Administration from The Wharton School of the University of Pennsylvania. He currently holds FINRA Series 79, 63 and 24 licenses.